Search Results
Transgenomic Announces Medicare Coverage for Clopidogrel (Plavix®) Response Test
OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (TBIO) today announced that National Government Services, the designated Medicare fiscal intermediary in Connecticut, has confirmed coverage for its proprietary Clopidogrel Genetic Absorption Activation Panel (C-GAAP, formerly PGxPREDICT:Clopidogrel). As a result of this coverage, the 48 million Americans currently covered by Medicare will have access to this genetic test.